Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 14/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 8/20 | 0.37 |
| ▸ | PDE4C | Q08493 | 8/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 8/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | VEGFA | P15692 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | PDE5A | O76074 | 1/20 | 0.33 |
| ▸ | TNF | P01375 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11090872 | 1.00 | PDE4A (0.37) | PDE4APDE4BPDE4CPDE4DTSHR | |
| SCHEMBL11090868 | 1.00 | PDE4A (0.37) | PDE4APDE4BPDE4CPDE4DTSHR | |
| SCHEMBL1657244 | 0.81 | BUB1 (0.35) | PDE4APDE4BPDE4CPDE4DTSHR | |
| SCHEMBL1657246 | 0.81 | BUB1 (0.35) | PDE4APDE4BPDE4CPDE4DTSHR | |
| SCHEMBL2598644 | 0.81 | BUB1 (0.35) | PDE4APDE4BPDE4CPDE4DTSHR | |
| SCHEMBL5759844 | 0.76 | — | — | |
| SCHEMBL9070667 | 0.76 | — | — | |
| SCHEMBL3734132 | 0.76 | — | — | |
| SCHEMBL23070591 | 0.71 | BUB1 (0.33) | GAA | |
| SCHEMBL15208286 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030055297-A1 | An alkyl, cycloalkyl, arylalkyl dihydroxy compound useful as intermediates; a cost-effective preparation | ABBOTT LABORATORIES | 2003-03-20 | — | — | US | claimed |
| WO-2002081441-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED PYRROLIDINE NEURAMINIDASE INHIBITORS | ABBOTT LABORATORIES (US) | 2002-10-17 | — | — | WO | claimed |
| EP-2097419-B1 | BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS | EXELIXIS INC (US) | 2011-05-25 | — | — | EP | disclosed |
| EP-2097419-B1 | BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS | EXELIXIS INC (US) | 2011-05-25 | — | — | EP | disclosed |
| CN-101965351-A | Benzofuran pyrimidinones | EXELIXIS INC | 2011-02-02 | — | — | CN | disclosed |
| US-20090247559-A1 | Benzofuropyrimidinones | EXELIXIS, INC. (US) | 2009-10-01 | — | — | US | disclosed |
| US-20090247559-A1 | Benzofuropyrimidinones | EXELIXIS, INC. (US) | 2009-10-01 | — | — | US | disclosed |
| US-20090247559-A1 | Benzofuropyrimidinones | EXELIXIS, INC. (US) | 2009-10-01 | — | — | US | disclosed |
| EP-2097419-A1 | BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS | Exelixis, Inc. (US) | 2009-09-09 | — | — | EP | disclosed |
| WO-2009086264-A1 | BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS | EXELIXIS, INC. (US) | 2009-07-09 | — | — | WO | disclosed |
| WO-2009086264-A1 | BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS | EXELIXIS, INC. (US) | 2009-07-09 | — | — | WO | disclosed |
| US-5889178-A | N-(2,2-DIPHENYLETHYL)-DERIVATIVES | GLAXO GROUP LIMITED (GB) | 1999-03-30 | — | — | US | disclosed |
| US-5447944-A | Activating cerebral metabolism and protection against anoxic brain damage | TAIHO PHARMACEUTICAL COMPANY, LIMITED (JP) | 1995-09-05 | — | — | US | disclosed |
| EP-0373226-B1 | Carbamoyl-2-pyrrolidinone compounds | TAIHO PHARMACEUTICAL CO LTD (JP) | 1994-06-15 | — | — | EP | disclosed |
| US-5229402-A | Improving cerebral function | TAIHO PHARMACEUTICAL COMPANY, LTD. (JP) | 1993-07-20 | — | — | US | disclosed |
| EP-0373226-A1 | Carbamoyl-2-pyrrolidinone compounds | TAIHO PHARMACEUTICAL COMPANY, LIMITED (JP) | 1990-06-20 | — | — | EP | disclosed |
| US-4461906-A | IMPROVING INTELLECTUAL CAPACITY | HOFFMANN-LA ROCHE INC. (US) | 1984-07-24 | — | — | US | disclosed |
| EP-0024030-B1 | PYRROLIDINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1983-03-30 | — | — | EP | disclosed |
| EP-0024030-A1 | Pyrrolidine derivatives, processes for their preparation and pharmaceutical compositions containing them | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1981-02-18 | — | — | EP | disclosed |
| US-4173569-A | Preparation of pyrrolidine and pyrrolidin-2-one derivatives | I.S.F. SPA (IT) | 1979-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247559-A1 | Benzofuropyrimidinones | F12, BRI3BP, BRD1 | PDE4A 1011/4885PDE4B 1150/4885PDE4C 1092/4885 |
| US-20030055297-A1 | An alkyl, cycloalkyl, arylalkyl dihydroxy compound useful as intermediates; a cost-effective preparation | NEU4, NEU2, NEU1 | PDE4A 620/4885PDE4B 572/4885PDE4C 904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.